News | May 15, 2022
Merck KGaA first quarter earnings grows on higher volumes, margins
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
The management believes that its strong product pipeline, diversified innovative product portfolio, continued expansion into new geographies and FGMP accreditations will help sustain the growth momentum in the coming few years
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Ind-Ra maintains a neutral outlook for healthcare in FY23
Company expects strong organic growth in sales, EBITDA in 2022
Subscribe To Our Newsletter & Stay Updated
